Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment

  • Arroyo-Crespo, Juan J.
  • Armiñán, Ana
  • Charbonnier, David
  • Balzano-Nogueira, Leandro
  • Huertas-López, Francisco
  • Martí, Cristina
  • Forteza, Jerónimo
  • Conesa, A.
  • Vicent Docon, Maria Jesus
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] The intrinsic characteristics of the tumor microenvironment (TME), including acidic pH and overexpression of hydrolytic enzymes, offer an exciting opportunity for the rational design of TME-drug delivery systems (DDS). We developed and characterized a pH-responsive biodegradable poly-L-glutamic acid (PGA)-based combination conjugate family with the aim of optimizing anticancer effects. We obtained combination conjugates bearing Doxorubicin (Dox) and aminoglutethimide (AGM) with two Dox loadings and two different hydrazone pH sensitive linkers that promote the specific release of Dox from the polymeric backbone within the TME. Low Dox loading coupled with a short hydrazone linker yielded optimal effects on primary tumor growth, lung metastasis (-90% reduction), and toxicological profile in a preclinical metastatic triple-negative breast cancer (TNBC) murine model. The use of transcriptomic analysis helped us to identify the molecular mechanisms responsible for such results including a differential immunomodulation and cell death pathways among the conjugates. This data highlights the advantages of targeting the TME, the therapeutic value of polymer-based combination approaches, and the utility of -omits-based analysis to accelerate anticancer DDS., The authors would like to thank Dr. Stuart P. Atkinson for his collaboration in manuscript preparation and English revision, and Irene Borreda for essential immunohistological support. This work has been supported by the European Research Council (grant ERC-CoG-2014-648831 "MyNano") and the Spanish Ministry of Science and Innovation (CTQ2010-18195, SAF2013-44848-R, BES-2008-006801, IPT-2012-0712-010000, Programa I3, and BIO2015-71658-R). LBN is funded through a University of South Florida-Helmsley Foundation award. FHL is funded through NIH grant. Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with FEDER funds (PO FEDER of Comunitat Valenciana 2014-2020).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes

  • Andreu, Zoraida
  • Hidalgo, Marta R.
  • Masia, Esther
  • Romera-Giner, Sergio
  • Malmierca-Merlo, Pablo
  • López-Guerrero, José A.
  • García-García, Francisco
  • Vicent, María J.
[EN] Identifying novel breast cancer biomarkers will improve patient stratification, enhance therapeutic outcomes, and help develop non-invasive diagnostics. We compared the proteomic profiles of whole-cell and exosomal samples of representative breast cancer cell subtypes to evaluate the potential of extracellular vesicles as non-invasive disease biomarkers in liquid biopsies. Overall, differentially-expressed proteins in whole-cell and exosome samples (which included markers for invasion, metastasis, angiogenesis, and drug resistance) effectively discriminated subtypes; furthermore, our results confirmed that the proteomic profile of exosomes reflects breast cancer cell-of-origin, which underscores their potential as disease biomarkers. Our study will contribute to identifying biomarkers that support breast cancer patient stratification and developing novel therapeutic strategies. We include an open, interactive web tool to explore the data as a molecular resource that can explain the role of these protein signatures in breast cancer classification., This study was supported by the European Research Council (grant ERC-CoG-2014-648831 MyNano ) and the H2020 EU-OpenScreen-Drive project (grant agreement No. 823893). Our screening platform is part of the European Infrastructure, ERIC EUOpenScreen, and the Excellence Network, TeNTaCLES (Translational NeTwork for the CLinical application of Extracellular Vesicle-Tentacles-RED2018-102411-T). This research was also supported by the Spanish Ministry of Science and Innovation (PID2019-108806RBI00; PID2020-117211GB-I00; PID2021-124430OA-I00 funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by FEDER, UE; and partially funded by the Institute of Health Carlos III (project IMPaCT-Data, IMP/00019), co-funded by ERDF and CIBERONC (project n. CB22/12/00048). The proteomic analysis was performed in the proteomics facility of SCSIE University of Valencia, which belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. Agreement 2019 between IVO and the Association Mou-te per elles.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

Polyglutamic acid-based Crosslinked Doxorubicin Nanogels as an Anti-Metastatic Treatment for Triple Negative Breast Cancer

  • Duro-Castano, Aroa
  • Sousa-Herves, Ana
  • Armiñán, Ana
  • Charbonnier, David
  • Arroyo-Crespo, Juan José
  • Wedepohl, Stefanie
  • Calderón, Marcelo
  • Vicent, María J.
Preprint, Treatment of triple negative breast cancer (TNBC)-associated metastasis represents an unmet clinical need, and we lack effective therapeutics for a disease that exhibits high relapse rates and associates with poor patient outcomes. Advanced nanosized drug delivery systems may enhance the efficacy of first-line chemotherapeutics by altering drug pharmacokinetics and enhancing tumor/metastasis targeting to signif-icantly improve efficacy and safety. Herein, we propose the application of injectable poly-amino acid-based nanogels (NGs) as a versatile hydrophilic drug delivery platform for the treatment of TNBC lung metastasis. We prepared biocompatible and biodegradable cross-linked NGs from polyglutamic acid (PGA) loaded with the chemotherapeutic agent doxorubicin (DOX). Our optimized synthetic procedures generated NGs of ~100 nm in size and 25 wt% drug loading content that became rapidly internalized in TNBC cell lines and displayed IC50 values comparable to the free form of DOX. Importantly, PGA-DOX NGs significantly inhibited lung metastases and almost completely suppressed lymph node metastases in a spontaneously metastatic orthotopic mouse TNBC model. Overall, our newly developed PGA-DOX NGs represent a potentially effective therapeutic strategy for the treatment of TNBC metastases., A.S-H thanks MC IEF actions (Project 302717). We thank Dr. M. A. Molina for AFM experiments, Ser-vicio SEM Cordoba (Argentina), and Mario Soriano Navarro from the electron microscopy service for Cryo-TEM pictures at CIPF. The authors would also like to thank Dr. Stuart P. Atkinson for his collabo-ration in the revision of the manuscript. This work has been supported by the European Research Council (grant ERC-CoG-2014-648831 “MyNano”), by the Spanish Ministry of Science and Innovation (SAF2013-44848-R, SAF2016-80427-R, RTI2018-099227-B-I00), by a Marie Curie IEF (Project 302717), and the Bundesministerium für Bildung und Forschung (BMBF) through the NanoMatFutur award (13N12561). Part of the equipment employed in this work has been funded by Generalitat Valen-ciana and co-financed with FEDER funds (PO FEDER of Comunitat Valenciana 2014–2020)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A rationally designed polypeptide-based hybrid platform for targeted intranasal brain drug delivery

  • Conejos-Sánchez, Inmaculada
  • Sebastián, Víctor
  • Vicent, María J.
I. Conejos-Sánchez et al., Data will be made available on request., Intranasal administration represents a safe and non-invasive route for drug delivery to the brain; however, clinical translation remains limited due to anatomical and physiological barriers. We present a modular hybrid biomaterial platform (NanoInBrain) that bypasses the blood-brain barrier via the olfactory route and enables central nervous system (CNS) drug delivery. The platform integrates a rationally designed polypeptide-based nanocarrier with a depot-forming hydrogel vehicle - a hyaluronic acid-poly-L-glutamate crosspolymer (HA-CP, Yalic®) - adapted from dermatological applications to enhance nasal mucosal retention and brain uptake. We engineered the nanocarrier system using star-shaped poly-L-glutamate (StPGA) architectures and systematically tuned physicochemical properties to optimize mucosal interaction and CNS diffusion. We introduced mucoadhesive and mucodiffusive functionalities via C-terminal odorranalectin (OL) conjugation, which improved nasal epithelium permeation through receptor-mediated mechanisms. Redox-responsive disulfide crosslinking (StPGA-CL-SS) further enhanced mucosal transport by enabling thiol-mediated anchoring to mucin glycoproteins, outperforming inert click-crosslinked variants. Ex vivo Franz diffusion studies and a nasal-mucosa-on-chip model demonstrated robust permeation, with in vivo imaging confirming brain distribution and intracellular uptake in neurons and microglia. Incorporation of HA-CP prolonged nasal residence (∼4 h) and increased total brain accumulation while being well-tolerated. This new platform combines architectural tunability, bioresponsive surface chemistry, and depot-mediated delivery in a scalable, biocompatible nose-to-brain delivery system with potential for treating neurological disorders., This work was supported by the European Research Council (grant ERC-CoG-2014-648831 ″MyNano” and ERC-PoC- 2022-POC1 ″POLYBRAINT”) to M.J.V.); Health Foundation La Caixa Research Project NanoGBA (HR22-00602) and Caixa Impulse NanoERT (CI24-20222); the Spanish Ministry of Science, Innovation, and Universities (SAF2016-80427-R, PID2019-108806RB-I00 to M.J.V.; RTC-2017-6465-1, C.F-L Grant PTQ2018-010251 and D.M − B, Grant Industrial PhD DI-14-06926); the MINECO/FEDER, UE; European Regional Development Fund (ERDF) included in the ERDF operational program of Comunidad Valenciana 2014-2020; the Valencian Council for Education, Culture, University and Employment (CIPROM/2023/053) to J.M.G-V and V.H-P; the Valencian Innovation Agency (AVI) (L.T-C INNTAL31/19/005) and the Generalitat Valenciana (I.D-P, Grant VALi+d ACIF-2016-021 and BEFPI/2018/055). I.C-S. is funded by AEEC Junior Grant (Ref INVES211323CONE), and L.I.T.-S. has a predoctoral contract by the Valencian Council for Education, Universities and Employment (ACIF2021/420). VS acknowledges funding from project PID2024-160339OB-I00, PID2021-127847OB-I00, ‘Severo Ochoa’ Programme for Centres of Excellence in R&D of the Spanish Ministry of Science, Innovation and Universities (MICIU CEX2023-001286-S MICIU/AEI /10.13039/501100011033)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001286-S)., Peer reviewed